Patient-Centered Cell Therapy Access

The access gap in cell therapy is widening. Most eligible patients still do not receive treatment.

acCELLapy was formed to accelerate optimal delivery of cell therapy through partnerships with cancer providers and biotechnology companies, with a strong focus on community-centered access.

Talk to our team View scientific pipeline

What We Do

Build and scale practical cell therapy access models

We help cancer programs launch and expand safe, high-quality cell therapy delivery through planning, training, and co-managed operational support.

Our model connects providers and biotechs to reduce practical complexity, increase readiness, and improve patient throughput.

Why It Matters

More eligible patients can receive life-saving treatment

As therapies advance, the access bottleneck should not determine outcomes. Community-centered delivery infrastructure closes the gap between eligibility and treatment.

Faster readiness and consistent deployment can mean shorter time to treatment and broader equity in care.

Problem - Why the gap exists

Demand is accelerating, but delivery capacity is not.

Cell therapy treatment is concentrated in specialized centers, while most oncology patients are treated in community settings.

85% remain untreated

Historically, under one in six eligible patients receive cell therapy treatment.

Our Solution

Expand capacity in the community, so access scales with need.

Assess current program readiness and prioritize high-impact gaps.
Deliver implementation planning and peer-level training support.
Co-manage operational workflows for safer, faster treatment deployment.
Partner with biotechs to accelerate incremental therapy adoption.

Cell Therapy Flow

From Collection to Response: How Treatment Progresses

What is Cell Therapy?

Cell therapy uses immune cells to target tumor antigens. Patient or donor cells are extracted, expanded and/or modified in a lab, then infused back to fight specific cancer cells.

How is Cell Therapy delivered?

Cells are collected in outpatient settings, processed over weeks, then infused after preparative treatment. Programs provide close monitoring during recovery to ensure safe response.

What are the results?

Current therapies have shown compelling outcomes, including high response rates in approved indications. As therapies evolve, eligibility and access opportunities continue to expand.

Scientific Pipeline

Autologous and allogenic programs in focus

Cell therapy pipeline table
Program	Modality	Cell Type	Tumor Focus	Development Stage
CAR-T Expansion	Chimeric Antigen Receptor T-Cell	Autologous	Hematologic malignancies	Commercial deployment
TIL Advancement	Tumor-Infiltrating Lymphocytes	Autologous	Solid tumors	Clinical trials
Allogenic CAR-T	Donor-derived CAR-T	Allogenic	Hematologic malignancies	Pipeline development
NK Platform	Natural Killer Cell Therapy	Allogenic	Hematologic and solid tumors	Early-to-mid clinical

Contact

Let's improve access together

If you are interested in learning more about our services, complete the form and our team will follow up.